The Sentinel


Wednesday, March 16, 2022

Letter from the Editor - March

Hello JITC Readers,


Welcome to the latest edition of the JITC digest. If any of our readers will be in New Orleans next month for the 2022 American Association for Cancer Research (AACR) Annual Meeting, we hope you will stop by the SITC booth in the exhibition hall for an opportunity to interact in person with JITC Deputy Editor-in-Chief Dr. James L. Gulley during one of our two Meet the Editor Sessions scheduled for 11:50 a.m.–12:20 p.m. on Monday, April 11 and Tuesday, April 12.

If you won’t be traveling to AACR, you can always take a virtual trip back in time with our popular archive articles, spotlighting important publications from the journal’s recent past.

Of course, the main attraction for the JITC digest is the exciting new papers in the current issue. This month we have two original research articles and a short report from the Clinical/Translational Cancer Immunotherapy section as well as original research from the Immunotherapy Biomarkers section.

Martina Svenja Lutz and colleagues describe a new mechanism of tumor immune escape from bispecific antibody treatment mediated by platelet activation.

A pan-cancer predictor for immune-related toxicity after anti-PD-1 monotherapy based on germline variants in microRNAs and their targets is identified by Joanne Weidhaas et al.

Treatment with anti-CCR4 leads to regulatory T cell depletion and meaningful tumor control in a canine clinical trial enrolling dogs with spontaneous prostate cancer reported by Shingo Maeda and colleagues.

Dipti Thakkar and colleagues demonstrate tumor control and microenvironment remodeling in multiple models with a first-in-class rationally targeted and non-depleting IgG4 isotype anti-VISTA antibody. After reading this comprehensive and meticulous work, be sure to continue your reading on VISTA and other promising targets in JITC’s Immune Checkpoints Beyond PD-1 Series.

Best regards,

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer

Wednesday, February 16, 2022

Letter from the Editor - February


Hello JITC Readers,

pedro-romero_1__1_.jpgWelcome to the latest edition of the JITC digest, arriving in your inbox as the Winter Olympics are ongoing in Beijing, China. Perhaps our JITC readers may see some similarities between the biathletes’ precision target shooting and the specificity of CAR T cells eradicating tumors. While the thrill of reading a paper with provocative new data likely cannot compare to the adrenaline rush of landing a triple axel or speeding down a ski slope at a speed of more than 70 miles per hour, we know that JITC deserves a medal for the top-quality immunotherapy research appearing in the journal each month.

JITC would not even make it to the podium, however, without the volunteers who support the journal in a variety of capacities. This month’s special feature is dedicated to the family of JITC volunteers, including the anonymous peer reviewers who are so essential to maintaining the high standards of our journal and the social media editors who help spread the word about the latest immunotherapy research to a global audience.

The original research articles highlighted in this month’s digest feature three novel mechanisms to heat up cold tumors and one surprising strategy to potentiate adoptive cell therapies.

Alycia Gardner and colleagues reveal a new function for TIM-3 blockade in reorganization of the tumor microenvironment leading to enhanced functionality of intratumoral cytotoxic T cells.

Immune exclusion in pancreatic ductal adenocarcinoma is overcome by a novel bioavailable scavenger reagent by Francesco De Sanctis et al, who also provide evidence that telomerase expression may be amenable to targeting via adoptive cell therapy in this disease.

An engineered IL-2 with extended serum half-life and negligible binding to the high affinity receptor expressed on T regulatory cells is demonstrated to offer robust tumor control as monotherapy and in combination with anti-PD-1 and anti-CTLA-4 in multiple pre-clinical models by Rosemina Merchant and colleagues.

B cells are identified as necessary and sufficient for potentiation of adoptive cell therapies expanded in the presence of toll-like receptor 9 agonists, further adding to our emerging understanding of the role of non-CD8+ T cells in immunotherapy efficacy.

Warm Regards,

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer

Wednesday, January 19, 2022

Letter From the Editor - January

Hello JITC Readers,

Welcome to the New Year and one that happens to be of great significance to the journal, as JITC will celebrate its 10th anniversary in 2022. It is humbling to look back on how far JITC has come in the past 10 years, and we are all excited for what the future holds.
Of course, it is the top-caliber articles published in JITC that have supported the journal’s ascent to being among the most highly-ranked oncology and immunology journals. This past year was no exception, and we are highlighting some of the top-most accessed and downloaded articles from 2021 in this month’s special feature.
The original research spotlighted in this month’s digest offers new insights on a diverse array of emerging areas in the immunotherapy field.
Jinzhu Mao and colleagues offer a detailed metagenomic census of the gut microbiome in patients with hepatobiliary cancers being treated with immunotherapy, showing that the presence of many lower-level taxa is not “one-size-fits-all” for clinical benefit.
A novel feedback loop involving CCL18-mediated crosstalk between tumor-associated macrophages and ovarian carcinoma cells promoting epithelial-to-mesenchymal transition and other invasive characteristics is described by Lingli Long et al.
Sub-cytotoxic doses of a metabolite of the topoisomerase I inhibitor irinotecan were demonstrated to enhance responses to anti-PD-1 via activation of FOXO3 and enhanced tumor infiltration of natural killer cells by Young Min Chung and colleagues.
Finally, Giuseppe Minniti et al present the results of a retrospective study indicating that the addition of immunotherapy to postoperative stereotactic radiosurgery reduces the risk of leptomeningeal disease for patients with melanoma and non-small cell lung cancer brain metastases.
Looking forward to what is in store for 2022!

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer